Abstract:BackgroundPARP inhibitors (PARPi) have been licensed for the maintenance therapy of patients with metastatic pancreatic cancer carrying pathogenic germline BRCA1/2 mutations. However, mutations in BRCA1/2 are notably rare in pancreatic cancer.ObjectiveThere is a significant unmet clinical need to broaden the utility of PARPi.DesignRNA sequencing was performed to screen potential targets for PARPi sensitivity. The synthetic lethal effects were verified in patient-derived xenograft (PDX), xenograft and patient-derived organoid models. Mechanisms were explored via LC‒MS/MS, coimmunoprecipitation, laser microirradiation, immunofluorescence, the homologous recombination (HR) or non-homologous end joining (NHEJ) reporter system, in situ proximity ligation assay and live-cell time-lapse imaging analyses.ResultsTargeting protein for Xenopus kinesin-like protein 2 (TPX2) is an exploitable vulnerability. TPX2 was downregulated in PDX models sensitive to PARPi, and TPX2 inhibition conferred synthetic lethality to PARPi bothin vitroandin vivo. Mechanistically, TPX2 functions in a cell cycle-dependent manner. In the S/G2 phase, ATM-mediated TPX2 S634 phosphorylation promotes BRCA1 recruitment to double-strand breaks (DSBs) for HR repair, whereas non-phosphorylated TPX2 interacts with 53BP1 to recruit it for NHEJ. The balance between phosphorylated and non-phosphorylated TPX2 determines the DSB repair pathway choice. During mitosis, TPX2 phosphorylation enhances Aurora A activity, promoting mitotic progression and chromosomal stability. Targeting TPX2 S634 phosphorylation with a cell-penetrating peptide causes genomic instability and mitotic catastrophe and enhances PARPi sensitivity. Additionally, the inhibition of TPX2 or S634 phosphorylation combined with gemcitabine further sensitised pancreatic cancer to PARPi.ConclusionsOur findings revealed the dual-functional significance of TPX2 in controlling DNA DSB repair pathway choice and mitotic progression, suggesting a potential therapeutic strategy involving PARPi for patients with pancreatic cancer.

Targeting TPX2 Suppresses Proliferation and Promotes Apoptosis Via Repression of the PI3k/AKT/P21 Signaling Pathway and Activation of P53 Pathway in Breast Cancer

Targeting TPX2 suppresses proliferation and promotes apoptosis via repression of the PI3k/AKT/P21 signaling pathway and activation of p53 pathway in breast cancer.

TPX2 promotes migration and invasion of human breast cancer cells

TPX2 Gene Silencing Inhibits Cell Proliferation and Promotes Apoptosis Through Negative Regulation of AKT Signaling Pathway in Ovarian Cancer.

Tpx2 Regulates Tumor Growth in Human Cervical Carcinoma Cells

TPX2 Knockdown Suppressed Hepatocellular Carcinoma Cell Invasion Via Inactivating AKT Signaling and Inhibiting MMP2 and MMP9 Expression.

Targeting Protein for Xenopus Kinesin-Like Protein 2 Knockdown Enhances Radiation Sensitivity of Human Lung Squamous Carcinoma Cell

Overexpression of TPX2 is Associated with Progression and Prognosis of Prostate Cancer

Overexpressed Targeting Protein for Xklp2 (TPX2) Serves As a Promising Prognostic Marker and Therapeutic Target for Gastric Cancer.

The TPX2 Gene is a Promising Diagnostic and Therapeutic Target for Cervical Cancer.

Tpx2 is A Novel Prognostic Marker for the Growth and Metastasis of Colon Cancer

TPX2 mediates prostate cancer epithelial-mesenchymal transition through CDK1 regulated phosphorylation of ERK/GSK3β/SNAIL pathway

TPX2 Level Correlates with Cholangiocarcinoma Cell Proliferation, Apoptosis, and EMT.

TPX2 as a novel prognostic biomarker for hepatocellular carcinoma.

TPX2 Serves As a Novel Target for Expanding the Utility of PARPi in Pancreatic Cancer Through Conferring Synthetic Lethality

TPX 2 in Human Clear Cell Renal Carcinoma : Expression , Function and Prognostic Significance

TPX2 Promotes Glioma Cell Proliferation and Invasion Via Activation of the AKT Signaling Pathway.

TPX2 Enhances the Transcription Factor Activation of PXR and Enhances the Resistance of Hepatocellular Carcinoma Cells to Antitumor Drugs

TPX2 Promotes Ovarian Tumorigenesis by Interacting with Lamin A/C and Affecting Its Stability.

High TPX2 expression results in poor prognosis, and Sp1 mediates the coupling of the CX3CR1/CXCL10 chemokine pathway to the PI3K/Akt pathway through targeted inhibition of TPX2 in endometrial cancer

Validation of TPX2 As a Novel Prognostic Marker for Malignant Progression and Metastasis of Colon Cancer.